These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Treating myelodysplastic syndromes. Ryan C; McCann S IDrugs; 2005 Apr; 8(4):320-6. PubMed ID: 15800807 [TBL] [Abstract][Full Text] [Related]
4. Strategies for biology- and molecular-based treatment of myelodysplastic syndromes. Lindberg EH Curr Drug Targets; 2005 Sep; 6(6):713-25. PubMed ID: 16178803 [TBL] [Abstract][Full Text] [Related]
5. Drug insight: emerging new drugs in the treatment of myelodysplastic syndromes. Faderl S; Kantarjian HM Nat Clin Pract Oncol; 2005 Jul; 2(7):348-55. PubMed ID: 16075794 [TBL] [Abstract][Full Text] [Related]
6. Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease. Mohty R; Al Hamed R; Bazarbachi A; Brissot E; Nagler A; Zeidan A; Mohty M J Hematol Oncol; 2022 Aug; 15(1):124. PubMed ID: 36045390 [TBL] [Abstract][Full Text] [Related]
7. New approaches to the treatment of myelodysplasia. List AF Oncologist; 2002; 7 Suppl 1():39-49. PubMed ID: 11961208 [TBL] [Abstract][Full Text] [Related]
8. Myelodysplastic syndromes: From pathogenesis and prognosis to treatment. Fenaux P Semin Hematol; 2004 Apr; 41(2 Suppl 4):6-12. PubMed ID: 15190510 [TBL] [Abstract][Full Text] [Related]
15. The clinical use of DNA methyltransferase inhibitors in myelodysplastic syndromes. Abou Zahr A; Saad Aldin E; Barbarotta L; Podoltsev N; Zeidan AM Expert Rev Anticancer Ther; 2015; 15(9):1019-36. PubMed ID: 26292903 [TBL] [Abstract][Full Text] [Related]
16. [Recent advances in the treatment of myelodysplastic syndromes]. Gelsi-Boyer V; Vey N Rev Med Interne; 2006 Aug; 27(8):600-9. PubMed ID: 16713027 [TBL] [Abstract][Full Text] [Related]
17. Update on supportive care and new therapies: immunomodulatory drugs, growth factors and epigenetic-acting agents. Hellström-Lindberg E Hematology Am Soc Hematol Educ Program; 2005; ():161-6. PubMed ID: 16304375 [TBL] [Abstract][Full Text] [Related]
18. Genetic and Epigenetic Drug Targets in Myelodysplastic Syndromes. Stankov K; Stankov S; Katanic J Curr Pharm Des; 2017; 23(1):135-169. PubMed ID: 27697023 [TBL] [Abstract][Full Text] [Related]
19. Myelodysplasia: new approaches. Seiter K Curr Treat Options Oncol; 2013 Jun; 14(2):156-69. PubMed ID: 23436197 [TBL] [Abstract][Full Text] [Related]
20. More is better: combination therapies for myelodysplastic syndromes. Ornstein MC; Mukherjee S; Sekeres MA Best Pract Res Clin Haematol; 2015 Mar; 28(1):22-31. PubMed ID: 25659727 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]